SWOG Procedures for Submission and Review of Data Requests

Presented by: Shay Bellasea

SWOG Data Request Process

- SWOG makes research data available to:
  - Investigators – both SWOG members and external investigators.
  - Pharmaceutical companies.
- Data requests that include study endpoints will only be considered after the primary study analyses have been published.
- An investigator who wishes to use a SWOG dataset must make a formal request which is evaluated by the SWOG Executive Committee (EC). Upon approval, investigators will receive a SWOG EC letter of support.
- In addition to SWOG EC review and approval, the requesting investigator must also sign a Data Use Agreement (DUA) between the Investigator's Institution and SWOG.

SWOG Data Request Process

SWOG Data Sharing Request Template

- Accessible on the SWOG website, or via request to the Disease Committee Statistician or the SWOG Network Operations Center at protocols@swog.org.
- Key Items to Focus On:
  1. Thoughtful specification of objectives
  2. Assess lack of overlap with prior and ongoing work through literature review, discussions with study chair(s) and the disease committee.
  3. Confirm data elements are available
     (This will be covered at the end of the presentation.)
  4. Review by the Disease Committee Chair



SWOG CANCER RESEARCH NETWORK

SWOG Data Sharing Request

Title of Data Project:

Name of Requestor:

Requestor's Email Address & Telephone Number:

Name of Requestor's Institution:

Address of Requestor's Institution:

Requestor understands requested Data will be provided to Requestor at Requestor's Institution:

Yes☐ No☐

SWOG Clinical trial(s) from which Data is requested:

Has primary manuscript(s) of the SWOG Clinical trial(s) from which Data is requested been published:

Yes☐ No☐

Data Project objective(s):

Primary objective:

Secondary objective(s):

Brief Justification:

Rationale:

Background:

Significance:

Endpoints:

Primary endpoint:

Secondary endpoint(s):

Approach / Methods:

Statistical Plan:

Is this Data Sharing Request a collaborative effort involving additional Investigator(s) and / or Institutions(s):

Yes☐ No☐

If Yes, name participating Investigator(s) and Institution(s):

Investigator and Institution:

Data Sharing Request Form (Version 5.1.2024) p. 1

Publications using SWOG Data

- Prior to submission, all abstracts and manuscripts must be forwarded to the SWOG Publications Office (pubs@swog.org) to ensure compliance with Group policy.
- Abstracts prepared for submission to any society meetings or seminars must be submitted to the Publications Office **no later than two weeks prior to submission**, or as determined by contractually bound timelines, to allow for authorship review and circulation to appropriate reviewers.

SWOG Data Request Process

- See SWOG Policy No. 43 for more information.
- SWOG Policies are publicly available on SWOG.org.

SWOG CANCER RESEARCH NETWORK
http://swog.org

Policy Memorandum No. 43
Subject: Requests for Participant Data
Departments Affected: All

Page 1 of 5 pages
Original Release Date: April 2006
Revision Date: October 2019

REQUESTS FOR PATIENT DATA FROM SWOG STUDIES

NCTN/NCORP Data Archive

- NCTN/NCORP Data Archive is another resource for research proposals.
- Includes SWOG and **non-SWOG** coordinated trials.
- The archive contains clinical data from Phase II/III, Phase III, and select Phase II studies from:
    - Primary publications published after January 2015.
    - Non-primary publications presenting updated survival data published after April 2018.
- Search for and request NCI-sponsored clinical data here: https://nctn-data-archive.nci.nih.gov/
- A signed DUA with the NCI is required to access the data. A SWOG agreement is not needed.

SWOG.org Clinical Trials Search Tool

- How do you find trials that match your research goals?
- What data are available for those trials?





SWOG.org - Searching for Clinical Trials: Filters





SWOG.org - Searching for Clinical Trials: Filters



SWOG.org - Searching for Clinical Trials: Filters



SWOG.org - Searching for Clinical Trials: Filters



SWOG.org - Searching for Clinical Trials: Filters



SWOG.org - Searching for Clinical Trials: Filters



SWOG.org - Searching for Clinical Trials: Filters



SWOG.org – Identifying the Primary Statistician for a SWOG-led study



The Research Committee under which the primary clinical trial was conducted will be identified on the protocol abstract page on SWOG.org, as shown here.

- First, identify the Research Committee that is associated with the conduct of the primary clinical trial via the protocol abstract page on SWOG.org.
- The contact information for the Primary Statistician that supports the associated Research Committee can be found via the Staff webpage on SWOG.org.

SWOG.org – Identifying the Primary Statistician for a SWOG-led study



From SWOG.org, navigate to:
"The SWOG Network" >> "Our Staff"

SWOG Cancer Research Network

Statistics and Data Management Center -

Fred Hutchinson Cancer Center
1100 Fairview Avenue North, M3-C102
Seattle, WA 98109-1024
Phone: 206-667-4623
Fax: 206-667-4408

Cancer Research And Biostatistics
1505 Westlake Ave N, Ste 750
Seattle, WA 98109
Phone: 206-652-9711

- After identifying the Research Committee associated with the primary clinical trial:
  - The name and contact email for the Primary Statistician that supports the associated Research Committee is available via the Staff webpage on SWOG.org under the *SWOG Statistics and Data Management Center* office locations.
  - Note: Primary Statisticians work out of both the Fred Hutchinson Cancer Center (under Biostatistics Faculty) and Cancer Research and Biostatistics (under Biostatistics) locations.

SWOG.org Search Results



Includes ct.gov registry number.



"Table view" is condensed

Indicates whether the study has been published.

Clinical Trial Listing



Accrual

	discontinue the experimental treatment but may continue on FOLFIRI alone. Patients on both arms should continue study follow-up.
Activated	09/01/2016
Participants	ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS

Research committees

Gastrointestinal Cancer

Treatment

5-Fluorouracil Irinotecan Leucovorin Calcium ABT-888

Eligibility Criteria

Histologically or cytologically documented pancreatic adenocarcinoma. Pancreatic neuroendocrine tumors, lymphoma of the pancreas, or ampullary cancer are not eligible; Must have metastatic disease that is measurable, CT scans or MRIs of the chest, abdomen, and pelvis used to assess measurable disease must have been completed within 28 days prior to reg. CT Scans or MRIs used to assess non-measurable disease must have been completed within 42 days prior to reg.

Must not have history of brain mets; must have had one and only one prior regimen of systemic therapy for metastatic disease unless the patient received systemic therapy with gemcitabine/nab-paclitaxel for resectable or borderline/locally advanced unresectable disease and progressed with metastatic disease within 3 months of the past dose of systemic therapy; systemic therapy and chemoradiotherapy for tx of resectable, borderline resectable or locally advanced unresectable disease is allowed and does not count toward prior therapy for metastatic disease; must have completed systemic therapy at least 14 days prior to reg, any surgical procedure must have been

Research committees

Gastrointestinal Cancer

Treatment

5-Fluorouracil Irinotecan Leucovorin Calcium ABT-888

Eligibility Criteria

Publication Information

Publications link to papers

2021

Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second Line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

EG Chiorean;K Guthrie;P Philip;E Swisher;F Jalikis;M Pishvaian;J Berlin;M Noel;J Suga;I Garrido-Laguna;D Cardin;M Radke;M Duong;A Lowy;H Hochster Clinical Cancer Research, Dec 1;27(23):6314-6322

PMid: PMID34580114 | **PMC number:** PMC8639715

2020

Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-world Experiment

DD Kim;G Guzauskas;C Bennette;A Basu;D Veenstra;S Ramsey;JJ Carlson PharmacoEconomics Feb;38(2):171-179; 2019 Oct 21. doi: 10.1007/s40273-019-00848-8. [Epub ahead of print]

CTSU.org Website Access

- Site staff set up their CTEP-IAM account, register with Registration and Credentialing Repository (RCR), and ID.me
- To obtain/update CTEP-IAM account: https://ctepcore.nci.nih.gov/iam
- To register in the RCR: https://ctepcore.nci.nih.gov/rcr
- To set up ID.me account: https://ctep.cancer.gov/investigatorResources/NCI_CTEP_IAM_User_Access_Update.htm
- RCR Quick Reference Guide – Provides an overview of the CTEP-IAM and RCR registration process

Accessing Protocol-Specific information on CTSU.org



Search for protocols by title or protocol number OR browse for the protocol number in the left navigation pane.

Documents>>CIRB-approved Documents tab includes: Protocol and Consent

Documents>>Protocol-Related Documents tab: includes: Case Report Forms and Memos



Master Forms Set from a SWOG Trial

SWOG
S2205 ONSTUDY FORM

Patient Identifier ☐☐☐☐☐☐ **Study Identifier** S 2 2 0 5 **Registration Step** 1

Patient Initials _____ (L, F M)

Page: Onstudy: Participant and Disease Description

Instructions: Submit this form within 15 days of initial registration. Date is in **DD MON YYYY** format. Explain any blank fields or blank dates in the **Comments** section.

Performance Status	○ 0 ○ 1 ○ 2 ○ 3 ○ 4
Height	☐☐☐ cm
Weight	☐☐☐.☐ kg
What was the date of the history and physical exam?	☐☐ ☐☐☐ ☐☐☐☐
What was the date of the initial diagnosis of the solid tumor malignancy for which the participant is planning to receive taxane-based chemotherapy?	☐☐ ☐☐☐ ☐☐☐☐
What is the type of tumor for which the participant is receiving taxane-based chemotherapy?	○ Breast ○ Lung ○ Endometrium ○ Ovary ○ Other, specify_____
Did the participant have a history of skin or limb metastases?	○ Yes ○ No
Did the participant previously receive neurotoxic chemotherapy? *(e.g. taxanes, platinum agents, vinca alkaloids, or bortezomib)*	○ Yes ○ No
Did the participant have pre-existing clinical peripheral neuropathy?	○ Yes ○ No
Did the participant have a history of Raynaud's phenomenon?	○ Yes ○ No
Did the participant have a history of cold agglutinin disease?	○ Yes ○ No
Did the participant have a history of cryoglobulinemia?	○ Yes ○ No
Did the participant have a history of cryofibrinogenemia?	○ Yes ○ No
Did the participant have a history of post-traumatic cold dystrophy?	○ Yes ○ No
Did the participant have a history of peripheral arterial ischemia?	○ Yes ○ No
Did the participant have any open skin wounds or ulcers of the limbs?	○ Yes ○ No

SWOG
S2205 TREATMENT

Participant Identifier ☐☐☐☐☐☐ **Study Identifier** S 2 2 0 5 **Registration Step** 1

Participant Initials _____ (L, F M) **Cycle Number** ☐☐

Page: Treatment

TREATMENT FOR THIS CYCLE

If any assigned agent was not administered during this cycle, then leave Start Date and End Date empty, enter "0" for the total dose administered and complete the Treatment Adjustments form. If any assigned agent was withdrawn in a previous cycle, enter "No" for dose modifications and enter "0" for the planned doses and the total dose administered.

Treatment Name	Start Date	End Date	Planned Dose Per Administration	Planned Total Dose	Total Dose Administered
Paclitaxel	☐☐ ☐☐☐ ☐☐☐☐	☐☐ ☐☐☐ ☐☐☐☐	☐☐☐ mg/m²	☐☐☐.☐ mg	☐☐☐.☐ mg
Carboplatin	☐☐ ☐☐☐ ☐☐☐☐	☐☐ ☐☐☐ ☐☐☐☐	☐☐☐.☐ mg	☐☐☐.☐ mg	☐☐☐.☐ mg
Docetaxel	☐☐ ☐☐☐ ☐☐☐☐	☐☐ ☐☐☐ ☐☐☐☐	☐☐ mg/m²	☐☐☐.☐ mg	☐☐☐.☐ mg
Nab-Paclitaxel	☐☐ ☐☐☐ ☐☐☐☐	☐☐ ☐☐☐ ☐☐☐☐	☐☐☐ mg/m²	☐☐☐.☐ mg	☐☐☐.☐ mg

Will the participant continue to receive taxane therapy? ○ Yes ○ No

SWOG is committed to sharing data.

To ensure a successful data request application, do your homework to make certain that the proposal is sound and feasible.